Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02851849 · ClinicalTrials.gov registry record · Phase 2
A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT02851849: Completed Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Ligand Pharmaceuticals.
NCT02851849 is a Phase 2 study of Type 2 Diabetes Mellitus that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 148 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02851849, a Phase 2 study of Type 2 Diabetes Mellitus, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG LGD-6972-5 mg
- DRUG LGD-6972-10 mg
- DRUG LGD-6972-15 mg
Study Locations (20)
California
- - Huntington Park
- - Los Angeles
- - Montclair
- - North Hollywood
- - San Diego
Florida
- - Brooksville
- - Miami
- - Orlando
- - Tampa
Arizona
- - Chandler
- - Surprise
North Carolina
- - Durham
- - Greensboro
Alabama
- - Tuscumbia
Colorado
- - Denver
Illinois
- - Chicago
Nevada
- - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02851849 record still lists
NCT02851849 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02851849 names 20 study sites across 11 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT02851849 about?
NCT02851849 is a clinical study titled "A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)
What is the current status of trial NCT02851849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2016-09. Estimated completion is 2017-06.
What conditions does trial NCT02851849 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT02851849?
The interventions under investigation include: Placebo (OTHER), LGD-6972-5 mg (DRUG), LGD-6972-10 mg (DRUG), LGD-6972-15 mg (DRUG).
Who is sponsoring clinical trial NCT02851849?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02851849 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02851849's enrollment target sits among peer trials
148 46th of 130 higher than 85 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia